The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD)

Prat, Laura Iogna; Tsochatzis, Emmanuel

doi:10.1007/s42000-018-0021-9

Cited by 40 publications

(26 citation statements)

References 115 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To the best of our knowledge, this study is currently the first systematic review that evaluated the comprehensive effectiveness of physical activity on hepatic enzyme, serum lipid, glucose metabolism and intra-hepatic lipid content in western and Chinese NAFLD patients without T2DM. The study population was restricted to subjects with NAFLD without T2DM.Although matching with an adequate control population can reduce the bias to some extents, the lack of information in anti-diabetic drug use of participants could still be a problem, considering different antidiabetic medications have different effects on NAFLD [25]. We also excluded other factors that may have affected the meta-analysis results, such as diet adjustment or lipid-lowering medication.…”

Section: Discussionmentioning

confidence: 99%

Physical activity intervention for non-diabetic patients with non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials

et al. 2020

View full text Add to dashboard Cite

Background: Non-alcoholic fatty liver disease (NAFLD) is currently the most common cause of chronic liver disease nowadays. Changes in diet and lifestyle have led to a dramatic increase in the prevalence of NAFLD around the world. This meta-analysis is to investigate the efficacy of physical activity intervention on liver-specific endpoints in the population with NAFLD, including hepatic enzyme, serum lipid, glucose metabolism and intra-hepatic lipid. Methods: PubMed and China National Knowledge Infrastructure (CNKI) databases were searched for randomized clinical trials of physical activity intervention on NAFLD patients through April 20th, 2019. Effect sizes were reported as standardized mean difference (SMD) and 95% confidence intervals (CI). Quality of included studies was assessed according to the Cochrane risk of bias tool. Meta-analyses were conducted using random-effect or fixed-effect models depending on the significance of heterogeneity. Subgroup analyses according to types and duration of physical activity were conducted to investigate clinical variability. Results: Nine studies with a cumulative total of 951 participants met selection criteria. Physical activity was found associated with small reductions in hepatic enzyme parameters: ALT (SMD-0.17, 95% CI:-0.30 to − 0.05), AST (SMD-0.25, 95% CI: − 0.38, − 0.13) and GGT (SMD-0.22, 95% CI: − 0.36, − 0.08). Significant small improvements were also found in serum lipid parameters including TC (SMD = − 0.22, 95% CI: − 0.34, − 0.09), TG (SMD = − 0.18, 95% CI: − 0.31 to − 0.06) and LDL-C (SMD = − 0.26, 95% CI: − 0.39 to − 0.13). Significant improvement was also found in intrahepatic lipid content (SMD = − 0.21, 95% CI: − 0.36 to − 0.06) There was no difference between physical intervention group and control group in HDL and three glucose metabolism parameters. Subgroup analysis suggested both aerobic exercise alone and resistance exercise alone can improve most liver function and longer period of exercise generally had better improvement effect.

show abstract

Section: Discussionmentioning

confidence: 99%

Physical activity intervention for non-diabetic patients with non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials

et al. 2020

View full text Add to dashboard Cite

show abstract

“…These classes include metformin, sulfonylureas, thiazolidinediones, dipeptidyl peptidase 4 inhibitors, glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, and insulin [ 154 ]. Substantial research has been made over the last years in order to find among the existing antidiabetic drugs other potential tools that can be used in T2DM-NAFLD patients [ 155 ].…”

Section: Therapeutic Optionsmentioning

confidence: 99%

The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD)

Tănase

Gosav

Costea

et al. 2020

Journal of Diabetes Research

279

180

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) remain as one of the most global problematic metabolic diseases with rapidly increasing prevalence and incidence. Epidemiological studies noted that T2DM patients have by two-fold increase to develop NAFLD, and vice versa. This complex and intricate association is supported and mediated by insulin resistance (IR). In this review, we discuss the NAFLD immunopathogenesis, connection with IR and T2DM, the role of screening and noninvasive tools, and mostly the impact of the current antidiabetic drugs on steatosis liver and new potential therapeutic targets.

show abstract

“…There is currently no established therapy for NAFLD/NASH. The only interventions that have proven to be effective are weight loss and physical activity [ 14 ]. The benefits of metformin in inhibiting hepatic gluconeogenesis, modifying hepatic fatty acid metabolism (including inhibition of adipose-tissue lipolysis), elevating of fatty acid oxidation, as well as inhibiting lipogenesis and enhancing insulin sensitivity are well-established [ 4 , 15 ].…”

Section: Metformin Improves Nonalcoholic Fatty Liver Diseasementioning

confidence: 99%

Metformin: An Old Drug with New Applications

Zhou

Massey

Story

et al. 2018

IJMS

177

124

View full text Add to dashboard Cite

Metformin is a biguanide drug that has been used to treat type 2 diabetes mellitus for more than 60 years. The United Kingdom Prospective Diabetic Study (UKPDS) has shown metformin to improve mortality rates in diabetes patients, and recent studies suggest metformin has additional effects in treating cancer, obesity, nonalcoholic fatty liver disease (NAFLD), polycystic ovary syndrome (PCOS), and metabolic syndrome. Metformin has also been shown to alleviate weight gain associated with antipsychotic medication. Metformin has recently been extensively studied and emerging evidence suggests metformin decreases hepatocyte triglyceride accumulation in NAFLD and prevents liver tumorigenesis. Interestingly, studies have also shown metformin reduces visceral fat, suppresses white-adipose-tissue (WAT) extracellular matrix remodeling, and inhibits obesity-induced inflammation. However, clinical evidence for using metformin to treat NAFLD, cancer, metabolic syndrome, or to prevent hepatocellular carcinoma in NAFLD patients is lacking. This review therefore addresses the potential beneficial effects of metformin on NAFLD, its role in protecting against cardiac ischemia–reperfusion (I/R) injury, atherosclerosis, glucotoxicity, and lipotoxicity induced oxidative and ER stress in pancreatic β-cell dysfunction, as well as its underlying molecular mechanisms of action.

show abstract

The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD)

Cited by 40 publications

References 115 publications

Physical activity intervention for non-diabetic patients with non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials

Physical activity intervention for non-diabetic patients with non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials

The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD)

Metformin: An Old Drug with New Applications

Contact Info

Product

Resources

About